Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis B Blood-Borne Infections Communicable Diseases DNA Virus Infections Digestive System Diseases Hepadnaviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases Virus Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

H. Consorci Sanitari Parc Tauli

Sabadell, Barcelona, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all those patients who have been seen in outpatient hepatology consultations and who present positive HBsAg and HBsAc serology simultaneously.

Exclusion criteria

Hepatitis C or HIV Co-infection

Treatment and study plan

Primary outcomes

prevalence concomitant HBsAg and HBsAc markers

Time frame: 10 years

To describe the prevalence of concomitant HBsAg and HBsAc markers in our area

Secondary outcomes

differences between immunocompetent patients with respect to immunocompromised ones.

Time frame: 10 years

To compare if there are differences in the prevalence or clinical outcome according if the patient has any degree of immunosupresion or not.

Sponsors and collaborators

Lead sponsor

Corporacion Parc Tauli

Other

Collaborators

Consorci Sanitari de Terrassa
Germans Trias i Pujol Hospital
Hospital Mutua de Terrassa
Hospital Universitario La Fe

Registry information

Official study title

Characteristics of Hepatitis B HBsAg & HBsAc Carriers Simultaneously

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Jul 6, 2022
Registry last updated: May 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed